Darwin AG Announces Preliminary Group Revenue for 2025 and Confirms Strategic Growth Trajectory

Munich, 25 February 2026 — 10:00 CET/CEST

Darwin AG (ISIN DE000A3C35W0) disclosed preliminary consolidated revenue figures for 2025, reporting approximately €55 million compared to €25.3 million in the prior year — representing 117% growth. The company also anticipates reporting a positive consolidated net result.

CEO Dr. Daniel Wallerstorfer stated: “We are very satisfied with the development of consolidated revenues in the 2025 financial year. The preliminary revenue figures underline the operational strength of our group.” He highlighted that subsidiary Novogenia GmbH’s genetic analysis products and personalized nutritional supplements have achieved international recognition. Wallerstorfer noted that partnerships with 10X Health (USA) and M42 (Abu Dhabi) “form the foundation for a new phase of scaling” and represent “significant potential for sustainable value creation.”

Complete audited consolidated financial figures and the 2025 Annual Report will be published May 12, 2026.

About Novogenia AG (formerly Darwin AG): The Novogenia Group, headquartered in Munich, operates as a European healthcare company specializing in human genetics and personalized product development. The organization conducts genetic analyses in its own laboratory for disease diagnosis, treatment, prevention, and production of customized nutritional supplements and cosmetics. Novogenia also partners with healthcare professionals and holds biotech/life sciences investments.

Contact:
Novogenia AG (Investor Relations)
Brienner Str. 7, 80333 Munich
Tel: +49 89 20 500 450
investor.relations@novogenia.com

Originally distributed via EQS News under the company's then-current name, Darwin AG. Source: eqs-news.com.